The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02267525

Acronym

DIGEST

Enrollment

233

Registered

2014-10-17

Start date

2014-12-31

Completion date

2017-06-30

Last updated

2018-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroparesis

Keywords

Gastroparesis, Diabetic, Idiopathic

Brief summary

Study 0099 explores the efficacy and safety of multiple doses of velusetrag in the treatment of symptoms in subjects with diabetic or idiopathic gastroparesis. Three dose levels of velusetrag will be evaluated and compared to placebo for approximately 12 weeks of therapy. In addition, the study will be used to evaluate the psychometric properties of the Gastroparesis Rating Scale (GRS), a daily patient-reported outcome (PRO) measure.

Interventions

DRUGVelusetrag

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Symptoms of gastroparesis (eg, nausea, early satiety, fullness, bloating, upper abdominal pain, retching or vomiting) for at least 3 months prior to Screening * Composite score ≥2and \<5 on nausea, bloating, feeling excessively full after meals, and not able to finish a normal-sized meal items (on the GCSI-2W) at Screening * Delayed gastric emptying by either GES (gastric emptying scintigraphy) or GEBT(gastric emptying breath test) * Upper gastrointestinal obstruction ruled out by endoscopy or other imaging (eg, computed tomography) after the onset of gastroparesis symptoms * Willing to abstain from prohibited medications, including but not limited to, anticholinergics, acetylcholinesterase antagonists, or promotility medications (eg, metoclopramide, domperidone, prucalopride, erythromycin) for: 24 hours prior to gastric emptying test during Screening, if applicable; 24 hours prior to start of the Baseline period; and during the Baseline Period * GCSI-24H 7-day mean composite score ≥2.5 and \<5 at Day 1

Exclusion criteria

* If Type 1 or Type 2 diabetic, a glycosylated hemoglobin (HbA1c) level \>11% * Prior history of gastric surgery, including but not limited to gastrectomy, gastric bypass, gastric banding, pyloroplasty, vagotomy, or fundoplication, which has manipulated the natural anatomy of the stomach * History of intrapyloric botulinum toxin injection within 3 months of Screening or currently has functioning implantable electric stimulator * History of alcohol or drug abuse or dependence within the last year prior to Screening

Design outcomes

Primary

Measure	Time frame
7-day mean GCSI-24H (Gastroparesis Cardinal Symptoms Index) composite score	At Week 4

Secondary

Measure	Time frame
Gastric emptying half-time	At Week 4
Adverse events	103 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026